title: Lack of effectiveness of several chelators in removing internally deposited strontium from mice following repeated parenteral strontium administration.
abstract: Diethylenetriaminepentaacetic acid (DTPA), ethylenglycolbis-(beta-amino-ethylether)-N,N-tetraacetic acid (EGTA), tartaric acid, KRYPTOFIX 222, and KRYPTOFIX 5 were evaluated for their efficacy in mobilization of strontium from the body of mice which had received 20 sc injections of strontium nitrate (95 mg/kg/injection) for 4 w. Twenty-four hours after the last strontium injection, ip administration of 1 of the various chelators or 0.9% saline was initiated and continued daily for 5 d. Mice were housed in metabolic cages, and urine and feces were collected daily for 5 d. After this period, the animals were killed and tissues removed. Tartaric acid, KRYPTOFIX 222, and KRYPTOFIX 5 had no effect on urinary or fecal strontium elimination, whereas DTPA and EGTA significantly decreased the fecal strontium excretion. The concentration of strontium in bone was only lowered in tartaric-treated mice. This study indicates the use of the above chelators is not an effective treatment to enhance the removal of strontium following repeated parenteral strontium administration.
authors.affiliation: Laboratory of Toxicology and Biochemistry, School of Medicine, University of Barcelona, Reus, Spain.
authors.forename: J M
authors.initials: JM
authors.lastname: Llobet
authors.forename: M T
authors.initials: MT
authors.lastname: Colomina
authors.forename: J L
authors.initials: JL
authors.lastname: Domingo
authors.forename: J
authors.initials: J
authors.lastname: Corbella
mesh_terms: D000818:Animals; D001643:Bridged Bicyclo Compounds / Q000627:therapeutic use; D019086:Bridged Bicyclo Compounds, Heterocyclic; D002614:Chelating Agents / Q000627:therapeutic use*; D015913:Chelation Therapy; D004533:Egtazic Acid / Q000627:therapeutic use; D004988:Ethers, Cyclic / Q000627:therapeutic use; D005243:Feces / Q000737:chemistry; D008297:Male; D051379:Mice; D004369:Pentetic Acid / Q000627:therapeutic use; D013324:Strontium / Q000378:metabolism*; D013644:Tartrates / Q000627:therapeutic use
chemical_list: D001643:Bridged Bicyclo Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; D002614:Chelating Agents; D004988:Ethers, Cyclic; D013644:Tartrates; C006071:cryptating agent 222; D004533:Egtazic Acid; C016270:1,11-bis(8-quinolinyloxy)-3,6,9-trioxaundecane; D004369:Pentetic Acid; C029768:tartaric acid; D013324:Strontium